Schedule 13D ownership disclosure
NLS PHARMACEUTICS LTD
Common Share, Par Value CHF 0.03 Per Share · CUSIP: H57830103
Event date: 2025-05-22
- Filing-level shares
- 557,131.00
- Percent of class
- 13.2%
- Ronald HafnerReported CIK 0002045580
Shares: 557,131.00 · Class: 13.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-057281
- Form type
- SCHEDULE 13D
- Filer
- Hafner Ronald
- CIK
- CIK 2045580
- Filed
- Jun 24, 2025
- Reporting period
- May 22, 2025
- Description
- Schedule 13D beneficial ownership